Main Management ETF Advisors »

Crispr Therapeutics shares owned by Main Management ETF Advisors

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Main Management ETF Advisors from 13F filings

Historical chart of Main Management ETF Advisors investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Main Management ETF Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Main Management ETF Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $693k 15k 47.00

More positions owned by Main Management ETF Advisors

Invesco Qqq Trust Series 1 (QQQ)
iShares S&P MidCap 400 Growth (IJK)
Select Sector Spdr Tr Communic etfeqty (XLC)
Vaneck Vectors Semiconductor Etf semiconductor (SMH)
Technology SPDR (XLK)
iShares S&P NA Tec.-SW. Idx. Fund (IGV)
Health Care SPDR (XLV)
iShares NASDAQ Biotechnology Index (IBB)
Ark Etf Tr gen rev mltsct (ARKG)
Consumer Discretionary SPDR (XLY)
Vanguard Energy ETF (VDE)
iShares S&P SmallCap 600 Index (IJR)
Franklin Templeton Etf Tr ftse japan etf (FLJP)
Franklin Templeton Etf Tr ftse china (FLCH)
iShares MSCI Netherlands Investable (EWN)

View all positions for Main Management ETF Advisors

Top funds holding Crispr Therapeutics

Capital Research and Management Company - Division 3
ARK Investment Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
BlackRock
BlackRock
T. Rowe Price Investment Management
State Street Corporation
Vanguard Group
NEA Management Company
Citadel Advisors
EcoR1 Capital
Susquehanna International
Bank of America Corporation
Sr One Capital Management

View all funds holding Crispr Therapeutics